INS Pre-Conference: Innovations in Neuromodulation

Innovations in Neuromodulation on 9 June 2013.

The International Neuromodulation Society (INS) is pleased to announce "Innovations in Neuromodulation," its second educational event for the neuromodulation innovation and investment community, which will take place on 9 June 2013, in Berlin, Germany, as part of the pre-conference of the INS 11th World Congress. This unique event will bring together over 200 leaders in the global neuromodulation community, the investment community and entrepreneurs, to share the wealth of their experiences, and their visions for the future of this exciting and rapidly evolving field. 

Preliminary Program

7.00 – 7.45      Breakfast

7.45 – 8.00      Welcome and Opening Remarks
                          INS Past President Dr. Elliot Krames, MD and
                          INS President Dr. Simon Thomson, MBBS, FRCA

8.00 – 8.30      Neuromodulation: Analysis of the Industry & Global Market
                          Eric Grigsby, MD, chief executive officer, Neurovations;
                          medical director, Napa Pain Clinic

8.30 – 9:30      Emerging Company Presentations: Enabling Therapy Delivery 
                          Highlights the critical role of interfacing with neural tissue in effective
                          neuromodulation and the innovation focused in this critical area.

     8.30 – 8.42 - Aleva Neurotherapeutics SA
     8.42 – 8.54 - Biotectix, LLC
     8.54 – 9.06 - NeuroNexus
     9.06 – 9.18 - WISE S.r.l.
     9.18 – 9.30 - Q & A

9.30 – 10.00    Formalizing Ideas & Protecting Intellectual Property
                          Danny Sachs, MD, Founder of Respicardia, Mainstay, Kspine, &
                          Amphora

10.00 – 10.30  Networking Break

10.30 – 11.20  Emerging Company Presentations: Innovation Platforms
                           Highlights the development of foundational platforms that will
                           enable others to develop novel therapeutic solutions through
                           leverage of a flexible platform.

     10.30 – 10.42 - Algostim, LLC.
     10.42 – 10.54 - Stimwave Technologies, Inc.
     10.54 – 11.06 - Sapiens Steering Brain Stimulation BV
     11.06 – 11.20 - Q & A

11.20 – 12.00   How to Raise Capital for a Startup Company Rami Elghandour,
                          Chief Business Officer,Nevro Corp.

12.00 – 13.30   Lunch & Keynote Presentation Chris Chavez, Chairman, President
                           and CEO, TriVascular, Inc. and former CEO and Director,
                           Advanced Neuromodulation Systems, Inc.

13.30 – 14.30  Emerging Company Presentations: Externals and Planning
                           Highlights the role of external instrumentation in the delivery of 
                           neuromodulation. This group includes companies providing 
                           systems that stimulate the various targets throughout the nervous 
                           system, as well as enable more effective chronic stimulation 
                           through image-guided planning and therapy.
                           Elliot Krames, MD, Moderator

     13.30 – 13.42 - NeuroSigma, Inc.
     13.42 – 13.54 - Neurotargeting LLC
     13.54 – 14.06 - Nexstim Oy
     14.06 – 14.30 - Q & A

14.30 – 15.30  Regulatory Pathway: FDA Approval and CE Mark Designation
                           Simon Thomson, MBBS, FRCA, Moderator
    14.30 – 14.55 Regulatory Approval Requirements - US and EC - Recent Trends
                              Winifred Wu, president, Strategic Regulatory Partners, LLC
    14.55 – 15.20 - Evidence for Payers – Rod Taylor, PhD, Health Services
                                 Research Professor, Exeter University
    15.20 – 15.30 - Q & A

15.30 – 16.30  Emerging Company Panel Presentations: New Therapy
                           Development - Highlights those who focus on creating new 
                           therapeutic solutions through neuromodulation.
                           Elliot Krames, Moderator

     15.30 – 15.42 - EndoStim
     15.42 – 15.54 - Functional Neuromodulation
     15.54 – 16.06 - Mainstay Medical
     16.06 – 16.18 - Neuros Medical, Inc.
     16.18 – 16.30 - Q & A

16.30  – 17.00  Networking Break

17.00 – 17.50  What Big Companies Look for When They Buy Small Companies
                           Don Deyo, CEO, MedTech Execs and former Vice President of
                           R&D, Medtronic Neuromodulation, moderator

    17.00 – 17.10 – Codman Neuro, division of Johnson & Johnson:
                                  Peter Stebbins, Vice President, Business Development
     17.10 – 17.20 – Medtronic: Jeff Erb, Sr. Director of Business Development,
                                  Alliances and IP Portfolio Management at Medtronic
     17.20 – 17.30 –  St. Jude Medical: Brad Maruca, Vice President,
                                  Product Marketing and Enterprise Connectivity
     17.30 – 17.40 – Sorin Group: Catherine Picard, Vice President, New Ventures
     17.40 – 17.50 – Q & A

17.50 – 18.00 Closing Comments

All delegates will be welcome to attend the INS Congress Opening Reception which will follow at 19.00 - 20.30.

Objectives
1. Learn about the process by which innovations occur, become funded and reach the marketplace.
2. Describe the process of establishing intellectual property.
3. Find out about current and future investment strategies and challenges in the device market --both in Europe and the U.S.
4. Define the regulatory process by which the CE Mark and FDA approval are obtained in Europe and the U.S., respectively.
5. Discover emerging companies and the science behind their innovative therapies.
6. Network with the leaders in innovation, investment, basic science and clinical practice in the neuromodulation space.

      l 2013 INS Congress Home l  8 June l 10 June l 11 June l 12 June l 13 June l